---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-042291"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2024-04-05T23:59:59+00:00"
generated_at: "2026-06-04T01:46:34.228084+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotech Q1 prelim rev ~$41-43M (+12% YoY); CFO Peterson departs, Piskel named

## Summary
- Preliminary total Q1 2024 revenue of ~$41-43M, up ~12% vs Q1 2023.
- MRD revenue ~$31-32M, up ~47% YoY; Immune Medicine revenue implied by difference.
- Strategic review concludes: run MRD and Immune Medicine internally with separate resources and segment reporting.
- CFO Tycho Peterson departs; Kyle Piskel (Principal Accounting Officer, 8-yr tenure) appointed full-time CFO.

## SEC filing metadata
- accession: 0000950170-24-042291
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2024-04-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000095017024042291/0000950170-24-042291-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000095017024042291/adpt-20240402.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-042291
- JSON: https://secwatch.observer/filing/0000950170-24-042291.json
- Plain text: https://secwatch.observer/filing/0000950170-24-042291.txt

## Key facts
- Earnings Releases
  Adaptive Biotechnologies Corp reported first quarter ended March 31, 2024 results: revenue approximately $41 to $43 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: approximately $41 to $43 million
  - Result: preliminary results
  source text: process and outcome of the strategic review during the conference call this afternoon. First Quarter 2024 Preliminary Unaudited Revenue Results • Total revenue of approximately $41 to $43 million for the first quarter of 2024, an increase of approximately 12% compared to the first quarter of 2023. • MRD revenue of approximately $31 to $32 million for the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000095017024042291/0000950170-24-042291-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.